Managing ESG Risk in Healthcare

Managing ESG Risk in Healthcare

Anuj A. Shah & Rob Larson • October 12, 2023
Anuj A. Shah & Rob Larson • October 12, 2023

Share

In the healthcare sector, the industry’s core mission revolves around enhancing and preserving lives, which can lead organizations to encounter a multifaceted array of Environmental, Social, and Governance (ESG) challenges. While these challenges are diverse and extend beyond the scope of this introduction, it's essential to identify, comprehend, and effectively manage them within a strategic ESG due diligence framework.

 

By taking a proactive approach to addressing ESG risks, organizations can ensure the delivery of equitable care, safeguarding of patient data, adherence to ethical business practices, and promotion of inclusivity in clinical trials. This comprehensive strategy not only ensures compliance but may also generate substantial value in a critical sector.

Identifying ESG Risks 

Within the healthcare industry, numerous pivotal ESG risks have been discerned; each serving as a fundamental catalyst in molding the future industry landscape. These risks form the core of our ESG due diligence framework and facilitate a comprehensive evaluation specific to an individual asset. Below, we delve into a select few key ESG risks within the domain:

Access to Care

Organizations delivering care or manufacturing medicines are under pressure to offer equitable access to care. They face reputational risks if they ignore the impact on groups of patients who are unequally afforded access to care. Ensuring access to quality healthcare for all is not only an ethical imperative but also a strategic necessity.

Patient Data Security

Patient data security is a direct risk for organizations that handle or protect patient data, including those involved in developing precision medicine. Safeguarding patient information is paramount not only to comply with regulations but also to maintain trust and confidence in healthcare services.

Business Ethics

Fee-for-service reimbursement models may incentivize health organizations to deliver more care than is medically necessary. This exposes them to regulatory and public scrutiny if ethical business practices are abused. Upholding the highest ethical standards in healthcare delivery is vital for maintaining public trust. 

Diversity & Inclusion in Clinical Trials

Companies developing medicines face growing public pressure to include a diverse and representative patient mix in clinical research trials. Ensuring diversity in clinical trials not only enhances the validity of research but also contributes to addressing healthcare disparities among different demographic groups.

ESG Due Diligence Process 

Stax’s ESG due diligence process involves a thorough assessment of material ESG risks across industries. We go beyond identification and provide strategic recommendations on how to track, monitor, and minimize risks during the ownership period. By implementing recommendations, organizations can ensure they are on the right path to meeting asset-specific ESG goals and responsibilities.


By proactively addressing ESG risks, organizations in the healthcare sector can enhance their reputations, strengthen patient trust, and contribute to the overall well-being of society. As the healthcare landscape evolves, it will become increasingly essential for organizations to embed ESG strategies into their operations, ensuring both patients and the healthcare ecosystem as a whole benefit. 

Image of Anuj A. Shah

Managing Director | ESG & Impact Advisory

Image of Rob Larson

Director | Healthcare

Read More

Will Barden Named Among The Consulting Report’s Top 25 Strategy Leaders of 2025
By Will Barden December 11, 2025
Will Barden, Partner, has been named among "The Consulting Report's" Top 25 Strategy Leaders of 2025. Click here to read more about the award.
Investing in Pharma Technology: A Healthcare Breakfast Discussion
By Rob Larson & Jordan Abrams December 8, 2025
In partnership with Raymond James and Farragut Square Group, Grant Thornton Stax recently hosted a breakfast event to share our investment analysis of the Pharma Technology market.
Miriam El-Baz & Connor Novy Honored as Consulting Magazine Women Leaders
December 2, 2025
Miriam El-Baz and Connor Novy were recognized at the Consulting Magazine Women Leaders awards to highlight the outstanding contributions made by women in consulting. Read more.
Featured in Financier Worldwide—Accelerating value in PE carve-outs: strategy and execution
By Phil Dunne & Peter Rodrigues-Renon November 11, 2025
Financier Worldwide discusses strategy & execution for accelerating value in carve-outs with Phil Dunne and Peter Rodrigues-Renon at Stax, including Gerard Nichol at Grant Thornton. Read more.
Key Considerations for Investors Exploring the Automotive Retail Tech Value Chain
By Sameer Tejani & Max Massaro November 6, 2025
Investment focus in automotive technology continues to broaden beyond OEMs to the core service ecosystem. Read what Sameer Tejani and Max Massaro see in the market.
Grant Thornton Stax Provides Sell-Side Support to SteelEye on its Merger With FundApps​
November 3, 2025
Grant Thornton Stax supported SteelEye, a leading trade and communications surveillance and data analytics platform, on its recent merger with FundApps. Read about the deal here.
Show More